Clinical Trials
5 trialsNCT06482905 2026-03-24
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT03423992 2021-06-15
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
Xuanwu Hospital, Beijing
Phase 1 Unknown
NCT02575261 2020-07-16
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT03252171 2020-07-16
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown